The University of Kansas Cancer Center will be a translational cancer facility purpose-built to advance and deliver cutting-edge cellular therapies. Designed to integrate research and clinical care, the new building will serve as a hub for Bone Marrow Transplant, immunotherapy, apheresis, and cell processing. Every element of the patient experience—from diagnostics and treatment to imaging, pathology, nutrition counseling, and social work—will take place in a single, coordinated environment.
The facility will expand access to innovative therapies developed on site, including CAR T-cell therapy, which reprograms a patient’s immune cells to attack cancer. The Cancer Center is the only center in the region offering all seven FDA-approved CAR T-cell therapies. A dedicated Good Manufacturing Practice (GMP) lab will enable in-house cell production, reducing treatment delays and supporting the rapid deployment of clinical advances.